SLC2A1 and Familial prostate cancer: The identification of FOXO1 and ATG5/GLUT1 in purified stroma and their differential expression in aggressive vs. indolent prostate cancer samples indicate that it is possible to clinically categorize PCa in terms of the metabolic responses, namely RWE, that it elicits in the stroma.